Phase 2 Pancreatic Cancer Trial, Recruiting NCT05929885 Sponsor: National Cancer Centre, Singapore Condition: Pancreatic Cancer
Back to Pancreatic Cancer

Phase 2 Pancreatic Cancer Trial, Recruiting

NCT05929885
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People aged 21 or older
  • People who have been diagnosed with pancreatic cancer confirmed by a tissue or cell sample
  • People whose cancer is at an advanced stage and cannot be fully removed by surgery (either locally advanced or spread to other parts of the body)
  • People whose cancer can be measured on scans using a standard set of measurement guidelines (confirm with trial site)
  • People whose doctors estimate they have a life expectancy of at least 12 weeks
  • People who are reasonably active and able to care for themselves, with only mild or no limitations on daily activities (confirm with trial site)
  • People whose blood cell counts are at an adequate level, as confirmed by blood tests
  • People whose liver is functioning well enough, as confirmed by blood tests
  • People whose kidneys are functioning well enough, as confirmed by blood tests
  • People who are able to give written consent to participate in the trial

Who may not be able to join:

  • People who have had another type of cancer within the past 5 years — though some exceptions may apply for certain early-stage or skin cancers, or for people who have been completely free of another cancer for at least 5 years after treatment
  • People who have untreated cancer spread to the brain or the lining of the brain and spinal cord — though people whose brain metastases have been treated, are causing no symptoms, and have been stable for 3 or more months may still be considered
  • People who have a serious ongoing illness, including severe infection, that could make it unsafe to take part in the trial procedures
  • People who have serious medical or mental health conditions that could make it difficult to follow the trial requirements
  • People who have received chemotherapy or radiation therapy aimed at managing symptoms within the 4 weeks before joining the trial
  • People who have had major surgery within 2 weeks before joining the trial
  • People who are currently taking long-term medications that suppress the immune system
  • People who are pregnant, breastfeeding, or not using adequate contraception — women who could become pregnant must have a negative pregnancy test within 3 days of joining, and men must either have had a surgical sterilisation procedure or agree to use a barrier method of contraception
  • People who are currently taking a specific type of blood-thinning medication known as vitamin K antagonists (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 23 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Dr Joycelyn LEE, MBBS, MRCP (UK), M Med, National Cancer Centre, Singapore

Phone: +65 64368000

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Sponsor
National Cancer Centre, Singapore
Registry
ClinicalTrials.gov
Start date
30 August 2023
Est. completion
28 February 2027

Where this trial is recruiting

🇸🇬 Singapore

Primary endpoints

Overall Response Rate (ORR).; Clinical Benefit Rate (CBR).; The Grade 3-5 Toxicity Rate.

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 23 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov